Comparing thigh injection experience across GLP-1 medications If you have experience with other GLP-1 receptor agonists, the thigh injection technique is largely the same
Start With a Free Weight Loss Consultation Your consultation may include a review of your goals, current weight, medical history, medications, previous weight loss attempts, appetite challenges, and treatment preferences
Home Medical news & Guidelines Anesthesiology Cardiology and CTVS Critical Care Dentistry Dermatology Diabetes and Endocrinology ENT Gastroenterology Medicine Nephrology Neurology Obstretics-Gynaecology Oncology Ophthalmology Orthopaedics Pediatrics-Neonatology Psychiatry Pulmonology Radiology Surgery Urology Laboratory Medicine Diet Nursing Paramedical Physiotherapy Health news Fact Check Bone Health Fact Check Brain Health Fact Check Cancer Related Fact Check Child Care Fact Check Dental and oral health fact check Diabetes and metabolic health fact check Diet and Nutrition Fact Check Eye and ENT Care Fact Check Fitness fact check Gut health fact check Heart health fact check Kidney health fact check Medical education fact check Men's health fact check Respiratory fact check Skin and hair care fact check Vaccine and Immunization fact check Women's health fact check AYUSH State News Andaman and Nicobar Islands Andhra Pradesh Arunachal Pradesh Assam Bihar Chandigarh Chattisgarh Dadra and Nagar Haveli Daman and Diu Delhi Goa Gujarat Haryana Himachal Pradesh Jammu & Kashmir Jharkhand Karnataka Kerala Ladakh Lakshadweep Madhya Pradesh Maharashtra Manipur Meghalaya Mizoram Nagaland Odisha Puducherry Punjab Rajasthan Sikkim Tamil Nadu Telangana Tripura Uttar Pradesh Uttrakhand West Bengal Medical Education Industry Semaglutide and Tirzepatide May Lower Dementia, Stroke, and Death Risk in Diabetic Patients With Obesity: Study Taiwan: A large-scale cohort study published in JAMA Network Open suggests that the use of GLP-1 receptor agonists, specifically semaglutide and tirzepatide, may offer protective benefits beyond blood sugar control in adults with type 2 diabetes and obesity
The factors driving discontinuation: GI side effects, age 65, lower income, and lack of meaningful weight loss early in treatment
